Pyronaridine-artesunate

Phase 3Small molecule

Pyronaridine-artesunate is one of 85 small molecule programs targeting Plasmodium falciparum malaria. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Plasmodium Falciparum MalariaActive, not recruiting

MalariaActive, not recruiting

Plasmodium Vivax MalariaActive, not recruiting

COVID-19Active, not recruiting

Plasmodium Falciparum MalariaPhase 3

Active, not recruiting

MalariaPhase 3

Active, not recruiting

Plasmodium Vivax MalariaPhase 3

Active, not recruiting

COVID-19Phase 2

Active, not recruiting

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

Pyronaridine-artesunate

Medicines for Malaria Venture

Phase 3

3 2

Stivarga

Bayer

Preclinical

1 3

Nexavar

Bayer

Preclinical

1 4

Tricor

JJagotec

Preclinical

1 5

Rayaldee

OOrganon and Co

Preclinical

1 6

Low-Molecular-Weight Heparin

Daiichi Sankyo

Preclinical

3 7

Statins

Sanofi

Preclinical

1 8

Olokizumab

UCB

Preclinical

1 9

Blood Collection

AAssistance Publique - Hôpitaux de Paris

Preclinical

1 10

Biological Collection

AAssistance Publique - Hôpitaux de Paris

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2029

Phase 3Recruiting

Malaria

NCT06962319

Clinical

Trials by Indication[1]

Malaria7 trials

Efficacy and Safety of Pyronaridine-artesunate for the Treatment in Uncomplicated Falciparum Malaria

Completed·UUniversity of Oxford·Phase 2·NCT02389439·123 enrolled

Health Systems Implementation and Molecular Surveillance of Multiple First-Line Treatments for Uncomplicated Malaria in Western Kenya

Completed·SStrathmore University··NCT07362498·316 enrolled

Safety of Antimalarials in the FIRst trimEster

Recruiting·LLiverpool School of Tropical Medicine·Phase 3·NCT06962319·1,510 enrolled

Show 4 more trials

Safety and Efficacy of Pyronaridine Artesunate Vs Chloroquine in Children and Adult Patients With Acute Vivax Malaria

Terminated· Medicines for Malaria Venture logo

Medicines for Malaria Venture·Phase 3·NCT04368910·30 enrolled

Pyronaridine Artesunate 3:1 Granule Formulation vs. Coartem© Crushed Tablets in P. Falciparum Malaria Pediatric Patients

Completed· Medicines for Malaria Venture logo

Medicines for Malaria Venture·Phase 3·NCT00541385·535 enrolled

Pyronaridine-artesunate and Artemether-lumefantrine for the Treatment of Paediatric Malaria

Completed·RRoyal Tropical Institute·Phase 3·NCT02411994·197 enrolled

Pyronaridine Artesunate (3:1) Versus Coartem® in P Falciparum Malaria Patients

Completed· Medicines for Malaria Venture logo

Medicines for Malaria Venture·Phase 3·NCT00422084·1,272 enrolled

COVID-193 trials

Malaria as a Risk Factor for COVID-19 in Western Kenya and Burkina Faso

Completed·LLiverpool School of Tropical Medicine·Phase 3·NCT04695197·143 enrolled

Four Different Experimental Drug Regimens to Standard of Care for the Treatment of Symptomatic Outpatients With COVID-19

Completed·SShin Poong Pharmaceutical Co. Ltd.·Phase 2·NCT04532931·192 enrolled

The Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 Patients

Completed·SShin Poong Pharmaceutical Co. Ltd.·Phase 2·NCT04475107·113 enrolled

Plasmodium falciparum malaria2 trials

Pyronaridine and Artesunate (3:1) in Children With Acute Uncomplicated Plasmodium Falciparum Malaria

Completed· Medicines for Malaria Venture logo

Medicines for Malaria Venture·Phase 2·NCT00331136·60 enrolled

Pyronaridine - Artesunate (3:1) Versus Mefloquine Plus Artesunate in Plasmodium Falciparum Malaria Patients

Completed· Medicines for Malaria Venture logo

Medicines for Malaria Venture·Phase 3·NCT00403260·1,271 enrolled

Plasmodium vivax malaria1 trial

Pyronaridine Artesunate (3:1) in Children and Adults With Acute Plasmodium Vivax Malaria

Completed· Medicines for Malaria Venture logo

Medicines for Malaria Venture·Phase 3·NCT00440999·456 enrolled

ART1 trial

Relative Bioavailability of Pyronaridine-artesunate in Tablet and Granule Formulations in Healthy Volunteers

Completed· Medicines for Malaria Venture logo

Medicines for Malaria Venture·Phase 1·NCT01868438·60 enrolled

2 more indications

Interaction1 trial

Drug Interaction Study of Pyronaridine-artesunate & Metoprolol, & Redosing Study of Pyronaridine-artesunate

Completed· Medicines for Malaria Venture logo

Medicines for Malaria Venture·Phase 1·NCT01523002·56 enrolled

Unspecified1 trial

Cohort Event Monitoring Study of Pyramax®

Completed·SShin Poong Pharmaceutical Co. Ltd.·Phase 4·NCT03201770·8,572 enrolled

Sources

References

[1]
ClinicalTrials.gov — 16 trial records for Pyronaridine-artesunate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Pyronaridine-artesunate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Pyronaridine-artesunate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Medicines for Malaria Venture company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Medicines for Malaria Venture

Pyronaridine-artesunate

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2029

Trials by Indication[1]

Malaria7 trials

COVID-193 trials

Plasmodium falciparum malaria2 trials

Plasmodium vivax malaria1 trial

ART1 trial

Interaction1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News